Kyprolis™

Generic Name: carfilzomib
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
2011-002CANCER - MULTIPLE MYELOMA3The primary objective of this study was to increase the body of safety data for carfilzomimb by providing expanded access to subjects with relapsed and refractory multiple myeloma who were unable to participate in other Onyx-sponsored carfilzomib studies ongoing in the United States (US)
2011-003CANCER - MULTIPLE MYELOMA3A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma
PX-171-001Hematological Malignancies1A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients with Hematological Malignancies: Two Week Cycle
PX-171-002HEMATOLOGIC MALIGNANCIES1A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients with Hematological Malignancies: Four-week Cycle
PX-171-003CANCER - MULTIPLE MYELOMA2An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma
PX-171-004CANCER - MULTIPLE MYELOMA2An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
PX-171-005CANCER - MULTIPLE MYELOMA2Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects with Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
PX-171-006CANCER - MULTIPLE MYELOMA1bPhase 1b Multicenter Dose Escalation Study of Carfilzomib with Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma
PX-171-007CANCER - MULTIPLE MYELOMA1b/2Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects with Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
PX-171-008Solid Tumors1bPhase lb Open-Label, Non-Randomized Study on the Effects of Carfilzomib on Pharmacokinetics of Midazolam in Subjects with Solid Tumors
PX-171-009CANCER - MULTIPLE MYELOMA3A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects with Relapsed Multiple Myeloma
PX-171-011CANCER - MULTIPLE MYELOMA3A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma